Abstract 69P
Background
PPIs taken before ICI may worsen outcomes in pts with solid tumors due to their gut microbiome disruptive effects, although no clear dose-dependent effect has been established yet.
Methods
We assessed the dose-dependent effects of PPIs on clinical outcomes in pts with stage IV solid tumors treated with PD-1/PD-L1 inhibitors at 17 Italian institutions from June 2014 to May 2020. PPI potency was standardized using the omeprazole equivalency (OE) method by Kirchheiner et al. An optimal OE cut-off was determined via the Youden index, categorizing pts into no PPI, low-potency PPI (≤13.5 mg/day OE), and high-potency PPI (>13.5 mg/day OE).
Results
Of the 675 pts included, 179 (26.5%) were on PPIs at baseline: 11.4% on low-potency and 15.1% on high-potency. Pts on PPIs were generally older, had poorer performance status (PS), higher disease burden, more baseline corticosteroid use, advanced-line treatment, and typically had non-small cell lung cancer. High-potency PPIs were associated with significantly worse overall survival (OS) (HR 1.55; 95% CI: 1.17-2.05) and progression-free survival (HR 2.02; 95% CI: 1.59-2.55) compared to no PPIs. Low-potency PPIs were not significantly associated with adverse outcomes. Multivariable Cox regression confirmed that only high-potency PPIs were associated with an increased risk of death (HR 1.55; 95% CI: 1.17-2.05), even after adjusting for potential confounders such as age, gender, PS, histology, disease burden, treatment line and baseline corticosteroid use. Double-adjusted propensity score matching confirmed the association between high-potency PPIs and poorer OS (HR 1.41; 95% CI: 1.04-1.92).
Conclusions
High-potency PPIs at baseline are associated with worse outcomes in pts treated with ICIs for stage IV solid tumors. Although further investigation is needed, these results suggest that PPIs should be used at the lowest effective dose to minimize potential detrimental effect.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session
145P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display session
Resources:
Abstract